Cases & Deals

Celgene prevails in district court case, beating back patent infringement claims directed against its Abraxane® brand cancer drug

Clients Celgene Corporation

Jones Day successfully defended Celgene Corporation and its subsidiary Abraxis BioScience, LLC in a patent infringement case brought in the United States District Court for the District of Massachusetts by Cephalon, Inc. and Acusphere, Inc. alleging Celgene's ABRAXANE® brand cancer drug infringed U.S. Patent No. RE40,493 ("the '493 patent'). After Jones Day obtained a favorable claim construction ruling, the plaintiffs agreed that ABRAXANE® did not infringe any valid claim of the '493 patent and stipulated to the entry of a final judgment of noninfringement.

Cephalon, Inc. et al. v. Celgene Corp. et al., Civil Action No. 1-11-cv-12226 (D. Mass.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.